Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of Three Novel Radiotracers for Imaging Aggregated Tau in Alzheimer's Disease with Positron Emission Tomography.
Gobbi LC, Knust H, Körner M, Honer M, Czech C, Belli S, Muri D, Edelmann MR, Hartung T, Erbsmehl I, Grall-Ulsemer S, Koblet A, Rueher M, Steiner S, Ravert HT, Mathews WB, Holt DP, Kuwabara H, Valentine H, Dannals RF, Wong DF, Borroni E. Gobbi LC, et al. Among authors: czech c. J Med Chem. 2017 Sep 14;60(17):7350-7370. doi: 10.1021/acs.jmedchem.7b00632. Epub 2017 Jul 12. J Med Chem. 2017. PMID: 28654263
Bis(arylvinyl)pyrazines, -pyrimidines, and -pyridazines as imaging agents for tau fibrils and β-amyloid plaques in Alzheimer's disease models.
Boländer A, Kieser D, Voss C, Bauer S, Schön C, Burgold S, Bittner T, Hölzer J, Heyny-von Haußen R, Mall G, Goetschy V, Czech C, Knust H, Berger R, Herms J, Hilger I, Schmidt B. Boländer A, et al. Among authors: czech c. J Med Chem. 2012 Nov 8;55(21):9170-80. doi: 10.1021/jm300653b. Epub 2012 Aug 31. J Med Chem. 2012. PMID: 22913544
Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).
Nave S, Doody RS, Boada M, Grimmer T, Savola JM, Delmar P, Pauly-Evers M, Nikolcheva T, Czech C, Borroni E, Ricci B, Dukart J, Mannino M, Carey T, Moran E, Gilaberte I, Muelhardt NM, Gerlach I, Santarelli L, Ostrowitzki S, Fontoura P. Nave S, et al. Among authors: czech c. J Alzheimers Dis. 2017;58(4):1217-1228. doi: 10.3233/JAD-161309. J Alzheimers Dis. 2017. PMID: 28550255 Free PMC article. Clinical Trial.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
Novel orally active, dibenzazepinone-based gamma-secretase inhibitors.
Peters JU, Galley G, Jacobsen H, Czech C, David-Pierson P, Kitas EA, Ozmen L. Peters JU, et al. Among authors: czech c. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5918-23. doi: 10.1016/j.bmcl.2007.07.078. Epub 2007 Aug 22. Bioorg Med Chem Lett. 2007. PMID: 17869099
115 results